LRRK2 and Parkinson disease: Overall, our data suggests the potential for using gene and/or protein expression levels of LRRK2, HMOX1, TLR2, TLR8, RELA, ATG7, and GABARAPL2 to follow therapeutic response with sargramostim during progression of PD.